Nephros Sees 40% Increase In Q2 Sales, Submits HDF Product For FDA Approval
Nephros Inc (NASDAQ:NEPH) has announced preliminary results and expects Q2 sales of approximately $2.2 million, representing a Y/Y increase of…
Stellantis Targets Electric Vehicles With $35.5B Plan: What Investors Need To Know
Stellantis NV (NYSE: STLA) on Thursday announced an aggressive plan to gain ground in the global electric vehicle market, saying it will spend 30 billion euros ($35.5 billion) by 2025 to add EVs with between 300 miles and 500 miles of range.
Digital Brands Group Estimates Q1 Revenues Increased 100% QoQ
Digital Brands Group, Inc. (the "Company" or "DBG") (NASDAQ:DBGI), a curated collection of luxury lifestyle, digital-first brands, announced that its initial estimate of financial
Why Tessco Shares Are Skyrocketing Today
TESSCO Technologies, Inc. (NASDAQ: TESS) shares are trading higher by 26% at $7.26 Thursday morning after the company issued first-quarter sales guidance above estimates.
Silicon Motion Sees Prelim. Q2 Revenue Growth ~20%, Above Original 5%-10% Range
Silicon Motion Technology Corporation (NASDAQ:SIMO) ("Silicon Motion" or the "Company"), a global leader in NAND flash controllers for solid state storage devices, announces that based on its
Safe-T Group Sees Sales Of $1.62M-$1.78M For The Quarter Ended Jun. 30, Up 50%-65% YoY
Safe-T® Group Ltd. (NASDAQ, TASE: SFET), a provider of secure access solutions and intelligent data collection, today provided an estimated revenue range for the three- and six-month periods ended June 30,
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 6)
Hollysys Sees FY21 Revs $560M-$595M Vs $547.8M Est
Outlook
"The Company provides an update on its financial outlook for the year ended June 30, 2021 ("FY2021"), an update from the outlook provided on August 13,
Immersion Sees Q2 Revs $10.5M-$11M Vs $8.05M Est
Revenues to be between $10.5 to $11.0 million
GAAP Operating expenses to be between $5.1 and $5.5 million
GAAP Net Income to be between $5.0 and $5.5
Biofrontera Sees June 2021 Revs €2.626M Vs €1.75M YoY
Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)))) (the "Company"), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of June 2021.
The